Chẩn đoán và điều trị AML ở người lớn: Khuyến nghị ELN 2017 từ một nhóm chuyên gia quốc tế

Döhner, 2010, Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, 115, 453, 10.1182/blood-2009-07-235358

Döhner, 2015, Acute myeloid leukemia, N Engl J Med, 373, 1136, 10.1056/NEJMra1406184

Arber, 2016, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, 127, 2391, 10.1182/blood-2016-03-643544

Arber

Sanz, 2009, Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet, Blood, 113, 1875, 10.1182/blood-2008-04-150250

Peterson

Gröschel, 2014, A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia, Cell, 157, 369, 10.1016/j.cell.2014.02.019

Yamazaki, 2014, A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression, Cancer Cell, 25, 415, 10.1016/j.ccr.2014.02.008

Nacheva, 2013, Does BCR/ABL1 positive acute myeloid leukaemia exist?, Br J Haematol, 161, 541, 10.1111/bjh.12301

Wouters, 2009, Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome, Blood, 113, 3088, 10.1182/blood-2008-09-179895

Pabst, 2009, Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis, Br J Cancer, 100, 1343, 10.1038/sj.bjc.6604977

Hou, 2009, Reply to ‘Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis’, Br J Cancer, 101, 738, 10.1038/sj.bjc.6605207

Green, 2010, Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations, J Clin Oncol, 28, 2739, 10.1200/JCO.2009.26.2501

Dufour, 2010, Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome, J Clin Oncol, 28, 570, 10.1200/JCO.2008.21.6010

Taskesen, 2011, Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity, Blood, 117, 2469, 10.1182/blood-2010-09-307280

Schlenk, 2013, The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA, Blood, 122, 1576, 10.1182/blood-2013-05-503847

Falini, 2010, Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1), Blood, 115, 3776, 10.1182/blood-2009-08-240457

Díaz-Beyá, 2010, The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status, Blood, 116, 6147, 10.1182/blood-2010-09-307314

Bacher, 2012, Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity, Blood, 119, 4719, 10.1182/blood-2011-12-395574

Tang, 2009, AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations, Blood, 114, 5352, 10.1182/blood-2009-05-223784

Gaidzik, 2011, RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group, J Clin Oncol, 29, 1364, 10.1200/JCO.2010.30.7926

Mendler, 2012, RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures, J Clin Oncol, 30, 3109, 10.1200/JCO.2011.40.6652

Gaidzik, 2016, RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features, Leukemia

Haferlach, 2016, The new provisional WHO entity ‘RUNX1 mutated AML’ shows specific genetics but no prognostic influence of dysplasia, Leukemia, 10.1038/leu.2016.150

Haferlach, 2009, AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features, Blood, 114, 3024, 10.1182/blood-2009-01-197871

Walter, 2013, Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients, Blood, 121, 2424, 10.1182/blood-2012-10-462440

Churpek, 2016, How I diagnose and manage individuals at risk for inherited myeloid malignancies, Blood, 128, 1800, 10.1182/blood-2016-05-670240

Polprasert, 2015, Inherited and somatic defects in DDX41 in myeloid neoplasms, Cancer Cell, 27, 658, 10.1016/j.ccell.2015.03.017

Zhang, 2015, Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy, Nat Genet, 47, 180, 10.1038/ng.3177

Harutyunyan, 2016, Germline RBBP6 mutations in familial myeloproliferative neoplasms, Blood, 127, 362, 10.1182/blood-2015-09-668673

Cancer Genome Atlas Research Network, 2013, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia, N Engl J Med, 368, 2059, 10.1056/NEJMoa1301689

Ley, 2010, DNMT3A mutations in acute myeloid leukemia, N Engl J Med, 363, 2424, 10.1056/NEJMoa1005143

Yan, 2011, Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia, Nat Genet, 43, 309, 10.1038/ng.788

Welch, 2012, The origin and evolution of mutations in acute myeloid leukemia, Cell, 150, 264, 10.1016/j.cell.2012.06.023

Ding, 2012, Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing, Nature, 481, 506, 10.1038/nature10738

Patel, 2012, Prognostic relevance of integrated genetic profiling in acute myeloid leukemia, N Engl J Med, 366, 1079, 10.1056/NEJMoa1112304

Papaemmanuil, 2016, Genomic classification and prognosis in acute myeloid leukemia, N Engl J Med, 374, 2209, 10.1056/NEJMoa1516192

Jan, 2012, Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia, Sci Transl Med, 4, 149ra118, 10.1126/scitranslmed.3004315

Krönke, 2013, Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia, Blood, 122, 100, 10.1182/blood-2013-01-479188

Corces-Zimmerman, 2014, Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission, Proc Natl Acad Sci USA, 111, 2548, 10.1073/pnas.1324297111

Shlush, 2014, Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia [published correction appears in Nature. 2014;508(7496):420], Nature, 506, 328, 10.1038/nature13038

Busque, 2012, Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis, Nat Genet, 44, 1179, 10.1038/ng.2413

Jaiswal, 2014, Age-related clonal hematopoiesis associated with adverse outcomes, N Engl J Med, 371, 2488, 10.1056/NEJMoa1408617

Xie, 2014, Age-related mutations associated with clonal hematopoietic expansion and malignancies, Nat Med, 20, 1472, 10.1038/nm.3733

Genovese, 2014, Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence, N Engl J Med, 371, 2477, 10.1056/NEJMoa1409405

McKerrell, 2015, Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis, Cell Reports, 10, 1239, 10.1016/j.celrep.2015.02.005

Steensma, 2015, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, 126, 9, 10.1182/blood-2015-03-631747

Béné, 2011, Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10, Leukemia, 25, 567, 10.1038/leu.2010.312

Grimwade, 2010, Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials, Blood, 116, 354, 10.1182/blood-2009-11-254441

Grimwade, 2016, Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance, Blood, 127, 29, 10.1182/blood-2015-07-604496

Gough, 2011, NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights, Blood, 118, 6247, 10.1182/blood-2011-07-328880

Hollink, 2011, NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern, Blood, 118, 3645, 10.1182/blood-2011-04-346643

Thol, 2013, Analysis of NUP98/NSD1 translocations in adult AML and MDS patients, Leukemia, 27, 750, 10.1038/leu.2012.249

Gruber, 2012, An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia, Cancer Cell, 22, 683, 10.1016/j.ccr.2012.10.007

McKerrell, 2016, Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies, Blood, 128, e1, 10.1182/blood-2015-11-683334

He, 2016, Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting, Blood, 127, 3004, 10.1182/blood-2015-08-664649

Gale, 2008, The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia, Blood, 111, 2776, 10.1182/blood-2007-08-109090

Pratcorona, 2013, Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy, Blood, 121, 2734, 10.1182/blood-2012-06-431122

Schlenk, 2014, Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation, Blood, 124, 3441, 10.1182/blood-2014-05-578070

Linch, 2014, Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia, Blood, 124, 273, 10.1182/blood-2014-02-554667

Stone, 2015, Midostaurin, a multi-targeted kinase inhibitor, improves overall survival when added to standard chemotherapy in adults age 18 – 60 with FLT3 mutant acute myeloid leukemia (AML): results from a randomized, prospective, placebo-controlled, double-blind trial, CALGB 10603/RATIFY [abstract], Blood, 126

Metzeler, 2011, ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category, Blood, 118, 6920, 10.1182/blood-2011-08-368225

Pratcorona, 2012, Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value, Haematologica, 97, 388, 10.3324/haematol.2011.051532

Schnittger, 2013, ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome, Leukemia, 27, 82, 10.1038/leu.2012.262

Paschka, 2015, ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group, Haematologica, 100, 324, 10.3324/haematol.2014.114157

Haferlach, 2008, Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype, Leukemia, 22, 1539, 10.1038/leu.2008.143

Bowen, 2009, TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis, Leukemia, 23, 203, 10.1038/leu.2008.173

Rücker, 2012, TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome, Blood, 119, 2114, 10.1182/blood-2011-08-375758

Devillier, 2015, Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes, Oncotarget, 6, 8388, 10.18632/oncotarget.3460

Tsai, 2016, Genetic alterations and their clinical implications in older patients with acute myeloid leukemia, Leukemia, 30, 1485, 10.1038/leu.2016.65

Churpek, 2015, Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia, Blood, 126, 2484, 10.1182/blood-2015-04-641100

Mujahed, 2015, Bone marrow fibroblasts derived from vitally frozen mononuclear cells as a source for germ line DNA in acute myeloid leukemia (AML) [abstract], Blood, 126, 10.1182/blood.V126.23.2606.2606

Metzeler, 2016, Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia, Blood, 128, 686, 10.1182/blood-2016-01-693879

Walter, 2011, Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment, J Clin Oncol, 29, 4417, 10.1200/JCO.2011.35.7525

Bullinger, Genomics of acute myeloid leukemia diagnosis and pathways, J Clin Oncol

Meyer, 2014, Translational implications of somatic genomics in acute myeloid leukaemia, Lancet Oncol, 15, e382, 10.1016/S1470-2045(14)70008-7

Ho, 2016, Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant FLT3-ITD, Biol Blood Marrow Transplant, 22, 462, 10.1016/j.bbmt.2015.10.023

Papaemmanuil, 2013, Clinical and biological implications of driver mutations in myelodysplastic syndromes, Blood, 122, 3616, 10.1182/blood-2013-08-518886

Haferlach, 2014, Landscape of genetic lesions in 944 patients with myelodysplastic syndromes, Leukemia, 28, 241, 10.1038/leu.2013.336

Taskesen, 2014, Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling, Blood, 123, 3327, 10.1182/blood-2013-07-512855

Lindsley, 2015, Acute myeloid leukemia ontogeny is defined by distinct somatic mutations, Blood, 125, 1367, 10.1182/blood-2014-11-610543

Vannucchi, 2013, Mutations and prognosis in primary myelofibrosis, Leukemia, 27, 1861, 10.1038/leu.2013.119

Paschka, 2013, Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?, Hematology Am Soc Hematol Educ Program, 10.1182/asheducation-2013.1.209

Allen, 2013, The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia, Leukemia, 27, 1891, 10.1038/leu.2013.186

Jourdan, 2013, Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia, Blood, 121, 2213, 10.1182/blood-2012-10-462879

Paschka, 2013, Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG), Blood, 121, 170, 10.1182/blood-2012-05-431486

Duployez, 2016, Comprehensive mutational profiling of core binding factor acute myeloid leukemia, Blood, 127, 2451, 10.1182/blood-2015-12-688705

Faber, 2016, The genomic landscape of core-binding factor acute myeloid leukemias, Nat Genet, 10.1038/ng.3709

Micol, 2014, Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations, Blood, 124, 1445, 10.1182/blood-2014-04-571018

Lavallée, 2016, Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors, Blood, 127, 3054, 10.1182/blood-2016-03-705053

Grimwade, 2014, Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?, Blood, 124, 3345, 10.1182/blood-2014-05-577593

Ossenkoppele, 2014, MRD in AML: it is time to change the definition of remission, Best Pract Res Clin Haematol, 27, 265, 10.1016/j.beha.2014.10.008

Buccisano, 2010, Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia, Blood, 116, 2295, 10.1182/blood-2009-12-258178

Inaba, 2012, Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia, J Clin Oncol, 30, 3625, 10.1200/JCO.2011.41.5323

Loken, 2012, Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children’s Oncology Group, Blood, 120, 1581, 10.1182/blood-2012-02-408336

Freeman, 2013, Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia, J Clin Oncol, 31, 4123, 10.1200/JCO.2013.49.1753

Terwijn, 2013, High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study, J Clin Oncol, 31, 3889, 10.1200/JCO.2012.45.9628

Chen, 2015, Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia, J Clin Oncol, 33, 1258, 10.1200/JCO.2014.58.3518

Araki, 2016, Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?, J Clin Oncol, 34, 329, 10.1200/JCO.2015.63.3826

Scholl, 2005, The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia, Haematologica, 90, 1626

Schnittger, 2009, Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML, Blood, 114, 2220, 10.1182/blood-2009-03-213389

Krönke, 2011, Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group, J Clin Oncol, 29, 2709, 10.1200/JCO.2011.35.0371

Shayegi, 2013, The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML, Blood, 122, 83, 10.1182/blood-2012-10-461749

Hubmann, 2014, Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse, Haematologica, 99, 1317, 10.3324/haematol.2014.104133

Lambert, 2014, MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin, Oncotarget, 5, 6280, 10.18632/oncotarget.2196

Ivey, 2016, Assessment of minimal residual disease in standard-risk AML, N Engl J Med, 374, 422, 10.1056/NEJMoa1507471

Corbacioglu, 2010, Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia, J Clin Oncol, 28, 3724, 10.1200/JCO.2010.28.6468

Yin, 2012, Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial, Blood, 120, 2826, 10.1182/blood-2012-06-435669

Zhu, 2013, MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial, Blood, 121, 4056, 10.1182/blood-2012-11-468348

Kohlmann, 2014, Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease, Leukemia, 28, 129, 10.1038/leu.2013.239

Klco, 2015, Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia, JAMA, 314, 811, 10.1001/jama.2015.9643

Pløen, 2014, Persistence of DNMT3A mutations at long-term remission in adult patients with AML, Br J Haematol, 167, 478, 10.1111/bjh.13062

Gaidzik, 2015, Monitoring of minimal residual disease (MRD) of DNMT3A mutations (DNMT3Amut) in acute myeloid leukemia (AML): a study of the AML Study Group (AMLSG) [abstract], Blood, 126, 10.1182/blood.V126.23.226.226

Mrózek, 2012, Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia, J Clin Oncol, 30, 4515, 10.1200/JCO.2012.43.4738

Micol, 2009, The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication, Blood, 114, 4601, 10.1182/blood-2009-07-230995

Breems, 2008, Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype, J Clin Oncol, 26, 4791, 10.1200/JCO.2008.16.0259

Medeiros, 2010, Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience, Blood, 116, 2224, 10.1182/blood-2010-02-270330

Kayser, 2012, Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies, Blood, 119, 551, 10.1182/blood-2011-07-367508

Cornelissen, 2012, Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories, J Clin Oncol, 30, 2140, 10.1200/JCO.2011.39.6499

Pasquini, 2016, Hematopoietic cell transplantation outcomes in monosomal karyotype myeloid malignancies, Biol Blood Marrow Transplant, 22, 248, 10.1016/j.bbmt.2015.08.024

Othus, 2016, Prediction of CR following a second course of ‘7+3’ in patients with newly diagnosed acute myeloid leukemia not in CR after a first course, Leukemia, 30, 1779, 10.1038/leu.2016.48

Ravandi, 2010, Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy, Blood, 116, 5818, 10.1182/blood-2010-07-296392

Burnett, 2013, Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial, J Clin Oncol, 31, 3360, 10.1200/JCO.2012.47.4874

Bejar, 2011, Clinical effect of point mutations in myelodysplastic syndromes, N Engl J Med, 364, 2496, 10.1056/NEJMoa1013343

Granfeldt Østgård, 2015, Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study, J Clin Oncol, 33, 3641, 10.1200/JCO.2014.60.0890

Bejar, 2012, Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes, J Clin Oncol, 30, 3376, 10.1200/JCO.2011.40.7379

Bejar, 2014, Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation, J Clin Oncol, 32, 2691, 10.1200/JCO.2013.52.3381

Greenberg, 2012, Revised international prognostic scoring system for myelodysplastic syndromes, Blood, 120, 2454, 10.1182/blood-2012-03-420489

Fenaux, 2009, Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study, Lancet Oncol, 10, 223, 10.1016/S1470-2045(09)70003-8

Krug, 2010, Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes, Lancet, 376, 2000, 10.1016/S0140-6736(10)62105-8

Kantarjian, 2006, Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome, Cancer, 106, 1090, 10.1002/cncr.21723

Klepin, 2014, Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia, Hematology Am Soc Hematol Educ Program, 2014, 8, 10.1182/asheducation-2014.1.8

Klepin, 2013, Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia, Blood, 121, 4287, 10.1182/blood-2012-12-471680

Deschler, 2013, Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome, Haematologica, 98, 208, 10.3324/haematol.2012.067892

Giles, 2007, The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia, Br J Haematol, 136, 624, 10.1111/j.1365-2141.2006.06476.x

Othus, 2014, Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson, Leukemia, 28, 289, 10.1038/leu.2013.176

Sorror

Dombret, 2016, An update of current treatments for adult acute myeloid leukemia, Blood, 127, 53, 10.1182/blood-2015-08-604520

Löwenberg, 2009, High-dose daunorubicin in older patients with acute myeloid leukemia [published correction appears in N Engl J Med. 2010;362(12):1155], N Engl J Med, 361, 1235, 10.1056/NEJMoa0901409

Fernandez, 2009, Anthracycline dose intensification in acute myeloid leukemia, N Engl J Med, 361, 1249, 10.1056/NEJMoa0904544

Lee, 2011, A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia, Blood, 118, 3832, 10.1182/blood-2011-06-361410

Burnett, 2015, A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients, Blood, 125, 3878, 10.1182/blood-2015-01-623447

Burnett, 2016, Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia, Blood, 128, 449, 10.1182/blood-2016-04-712091

Pautas, 2010, Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study, J Clin Oncol, 28, 808, 10.1200/JCO.2009.23.2652

Löwenberg, 2011, Cytarabine dose for acute myeloid leukemia, N Engl J Med, 364, 1027, 10.1056/NEJMoa1010222

Willemze, 2014, High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial, J Clin Oncol, 32, 219, 10.1200/JCO.2013.51.8571

Löwenberg, 2013, Sense and nonsense of high-dose cytarabine for acute myeloid leukemia, Blood, 121, 26, 10.1182/blood-2012-07-444851

Petersdorf, 2013, A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia, Blood, 121, 4854, 10.1182/blood-2013-01-466706

Burnett, 2011, Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial, J Clin Oncol, 29, 369, 10.1200/JCO.2010.31.4310

Burnett, 2012, Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia, J Clin Oncol, 30, 3924, 10.1200/JCO.2012.42.2964

Castaigne, 2012, Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study, Lancet, 379, 1508, 10.1016/S0140-6736(12)60485-1

Hills, 2014, Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials, Lancet Oncol, 15, 986, 10.1016/S1470-2045(14)70281-5

Amadori, 2013, Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17), J Clin Oncol, 31, 4424, 10.1200/JCO.2013.49.0771

Mayer, 2006, Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice, Mol Cancer Ther, 5, 1854, 10.1158/1535-7163.MCT-06-0118

Lancet, 2014, Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML, Blood, 123, 3239, 10.1182/blood-2013-12-540971

Cortes, 2015, Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML, Cancer, 121, 234, 10.1002/cncr.28974

Lancet, 2016, Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML [abstract], J Clin Oncol, 34

Breems, 2005, Prognostic index for adult patients with acute myeloid leukemia in first relapse, J Clin Oncol, 23, 1969, 10.1200/JCO.2005.06.027

Holowiecki, 2012, Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study, J Clin Oncol, 30, 2441, 10.1200/JCO.2011.37.1286

Burnett

Schaich, 2011, Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study, J Clin Oncol, 29, 2696, 10.1200/JCO.2010.33.7303

Miyawaki, 2011, A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study, Blood, 117, 2366, 10.1182/blood-2010-07-295279

Thomas, 2011, Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study, Blood, 118, 1754, 10.1182/blood-2011-04-349258

Itzykson, 2011, Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria, Haematologica, 96, 837, 10.3324/haematol.2010.036921

Vellenga, 2011, Autologous peripheral blood stem cell transplantation for acute myeloid leukemia, Blood, 118, 6037, 10.1182/blood-2011-07-370247

Pfirrmann, 2012, Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial, Lancet Oncol, 13, 207, 10.1016/S1470-2045(11)70326-6

Cornelissen, 2015, Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years, Leukemia, 29, 1041, 10.1038/leu.2014.332

Buyse, 2011, Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia, Blood, 117, 7007, 10.1182/blood-2011-02-337725

Löwenberg, 2010, Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study, Blood, 115, 2586, 10.1182/blood-2009-10-246470

Gratwohl, 2015, One million haemopoietic stem-cell transplants: a retrospective observational study, Lancet Haematol, 2, e91, 10.1016/S2352-3026(15)00028-9

Passweg, 2015, Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants, Bone Marrow Transplant, 50, 476, 10.1038/bmt.2014.312

Niederwieser, 2016, Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey, Bone Marrow Transplant, 51, 778, 10.1038/bmt.2016.18

Juliusson, 2011, Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006, Cancer, 117, 4238, 10.1002/cncr.26033

Cornelissen, 2012, The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach, Nat Rev Clin Oncol, 9, 579, 10.1038/nrclinonc.2012.150

Majhail, 2015, Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation, Biol Blood Marrow Transplant, 21, 1863, 10.1016/j.bbmt.2015.07.032

Sureda, 2015, Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015, Bone Marrow Transplant, 50, 1037, 10.1038/bmt.2015.6

Cornelissen, 2016, Hematopoietic stem cell transplantation for patients with AML in first complete remission, Blood, 127, 62, 10.1182/blood-2015-07-604546

Gorin, 2015, Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects., Bone Marrow Transplant, 50, 1495, 10.1038/bmt.2015.179

Sengsayadeth, 2015, Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT, Haematologica, 100, 859, 10.3324/haematol.2015.123331

Pingali, 2015, Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation, Bone Marrow Transplant, 50, 1157, 10.1038/bmt.2015.61

Storb, 2016, Nonmyeloablative allogeneic hematopoietic cell transplantation, Haematologica, 101, 521, 10.3324/haematol.2015.132860

Rambaldi, 2015, Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial, Lancet Oncol, 16, 1525, 10.1016/S1470-2045(15)00200-4

Martino, 2013, Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT, Bone Marrow Transplant, 48, 761, 10.1038/bmt.2012.236

Passweg, 2015, Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT, Bone Marrow Transplant, 50, 1063, 10.1038/bmt.2015.121

Scott

Copelan, 2013, Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI, Blood, 122, 3863, 10.1182/blood-2013-07-514448

Nagler, 2013, Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European Group for Blood and Marrow Transplantation, J Clin Oncol, 31, 3549, 10.1200/JCO.2013.48.8114

Bredeson, 2013, Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation, Blood, 122, 3871, 10.1182/blood-2013-08-519009

Elsawy, 2016, Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation, Bone Marrow Transplant, 51, 1283, 10.1038/bmt.2016.141

Sorror, 2014, Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation, J Clin Oncol, 32, 3249, 10.1200/JCO.2013.53.8157

Armand, 2014, Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation, Blood, 123, 3664, 10.1182/blood-2014-01-552984

Gratwohl, 1998, Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Lancet, 352, 1087, 10.1016/S0140-6736(98)03030-X

Versluis, 2015, Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission, Leukemia, 29, 51, 10.1038/leu.2014.164

Michelis, 2015, Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2, Bone Marrow Transplant, 50, 1405, 10.1038/bmt.2015.165

Soiffer, 2011, Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies, Blood, 117, 6963, 10.1182/blood-2011-01-332007

Pasquini, 2012, Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation, J Clin Oncol, 30, 3194, 10.1200/JCO.2012.41.7071

Bleakley, 2015, Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts, J Clin Invest, 125, 2677, 10.1172/JCI81229

Luznik, 2010, High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease, Blood, 115, 3224, 10.1182/blood-2009-11-251595

de Lima, 2014, Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation, Biol Blood Marrow Transplant, 20, 4, 10.1016/j.bbmt.2013.08.012

Mawad, 2014, Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome, Biol Blood Marrow Transplant, 20, 1363, 10.1016/j.bbmt.2014.05.014

Schiller, 2016, Allogeneic hematopoietic stem cell transplantation in FLT3-ITD-positive acute myelogenous leukemia: the role for FLT3 tyrosine kinase inhibitors post-transplantation, Biol Blood Marrow Transplant, 22, 982, 10.1016/j.bbmt.2016.01.013

Pusic, 2015, Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome, Biol Blood Marrow Transplant, 21, 1761, 10.1016/j.bbmt.2015.05.026

Craddock, 2016, Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA Trial, Biol Blood Marrow Transplant, 22, 385, 10.1016/j.bbmt.2015.09.004

Miller, 2013, Therapeutic applications: natural killer cells in the clinic, Hematology Am Soc Hematol Educ Program, 10.1182/asheducation-2013.1.247

Bachanova, 2014, Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein, Blood, 123, 3855, 10.1182/blood-2013-10-532531

Chapuis, 2013, Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients, Sci Transl Med, 5, 174ra27, 10.1126/scitranslmed.3004916

Mardiros, 2013, T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia, Blood, 122, 3138, 10.1182/blood-2012-12-474056

Kenderian, 2015, CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia, Leukemia, 29, 1637, 10.1038/leu.2015.52

Lynn, 2015, Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells, Blood, 125, 3466, 10.1182/blood-2014-11-612721

Ossenkoppele, 2015, How I treat the older patient with acute myeloid leukemia, Blood, 125, 767, 10.1182/blood-2014-08-551499

Sorror, 2015, Impact of comorbidities at diagnosis of acute myeloid leukemia on one-year mortality [abstract], Blood, 126, 10.1182/blood.V126.23.532.532

Burnett, 2007, A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment, Cancer, 109, 1114, 10.1002/cncr.22496

Kantarjian, 2012, Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia, J Clin Oncol, 30, 2670, 10.1200/JCO.2011.38.9429

Dombret, 2015, International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts, Blood, 126, 291, 10.1182/blood-2015-01-621664

Döhner, 2014, Overall survival in older patients with newly diagnosed acute myeloid leukemia (AML) with >30% bone marrow blasts treated with azacitidine by cytogenetic risk status: Results of the AZA-AML-001 study [abstract], Blood, 124, 10.1182/blood.V124.21.621.621

Fenaux, 2010, Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia, J Clin Oncol, 28, 562, 10.1200/JCO.2009.23.8329

Estey, 2013, Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia, Leukemia, 27, 1803, 10.1038/leu.2013.173

Thol, 2015, How I treat refractory and early relapsed acute myeloid leukemia, Blood, 126, 319, 10.1182/blood-2014-10-551911

Price, 2011, Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens, Leuk Res, 35, 301, 10.1016/j.leukres.2010.09.002

Faderl, 2012, Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial, J Clin Oncol, 30, 2492, 10.1200/JCO.2011.37.9743

Roboz, 2014, International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia, J Clin Oncol, 32, 1919, 10.1200/JCO.2013.52.8562

Ravandi, 2015, Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study, Lancet Oncol, 16, 1025, 10.1016/S1470-2045(15)00201-6

Itzykson, 2015, Azacitidine for the treatment of relapsed and refractory AML in older patients, Leuk Res, 39, 124, 10.1016/j.leukres.2014.11.009

Ivanoff, 2013, 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy, Am J Hematol, 88, 601, 10.1002/ajh.23464

Ritchie, 2013, Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia, Leuk Lymphoma, 54, 2003, 10.3109/10428194.2012.762093

Sarkozy, 2013, Outcome of older patients with acute myeloid leukemia in first relapse, Am J Hematol, 88, 758, 10.1002/ajh.23498

Burnett, 2013, Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission, J Clin Oncol, 31, 1293, 10.1200/JCO.2011.40.5977

Duval, 2010, Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure, J Clin Oncol, 28, 3730, 10.1200/JCO.2010.28.8852

Craddock, 2011, Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia, Leukemia, 25, 808, 10.1038/leu.2011.13

Jabbour, 2014, Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy, Am J Hematol, 89, 395, 10.1002/ajh.23655

Schmid, 2006, Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation, Blood, 108, 1092, 10.1182/blood-2005-10-4165

Holtick, 2016, FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission, Eur J Haematol, 96, 475, 10.1111/ejh.12615

Othus, 2015, Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy, Biol Blood Marrow Transplant, 21, 559, 10.1016/j.bbmt.2014.10.025

Bejanyan, 2015, Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study, Biol Blood Marrow Transplant, 21, 454, 10.1016/j.bbmt.2014.11.007

Ruutu, 2015, Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT, Bone Marrow Transplant, 50, 1542, 10.1038/bmt.2015.186

Schmid, 2007, Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party, J Clin Oncol, 25, 4938, 10.1200/JCO.2007.11.6053

Yan, 2013, Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors, Eur J Haematol, 91, 304, 10.1111/ejh.12168

Craddock, 2016, Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia, Haematologica, 101, 879, 10.3324/haematol.2015.140996

Schroeder, 2015, Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group, Biol Blood Marrow Transplant, 21, 653, 10.1016/j.bbmt.2014.12.016

Davids, 2016, Ipilimumab for patients with relapse after allogeneic transplantation, N Engl J Med, 375, 143, 10.1056/NEJMoa1601202

Churpek, 2013, The evolving challenge of therapy-related myeloid neoplasms, Best Pract Res Clin Haematol, 26, 309, 10.1016/j.beha.2013.09.001

Bhatia, 2013, Therapy-related myelodysplasia and acute myeloid leukemia, Semin Oncol, 40, 666, 10.1053/j.seminoncol.2013.09.013

Morton, 2013, Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008, Blood, 121, 2996, 10.1182/blood-2012-08-448068

Hulegårdh, 2015, Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry, Am J Hematol, 90, 208, 10.1002/ajh.23908

Christiansen, 2001, Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis, J Clin Oncol, 19, 1405, 10.1200/JCO.2001.19.5.1405

Shih, 2013, Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia, Haematologica, 98, 908, 10.3324/haematol.2012.076729

Cleven, 2015, High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome, Mod Pathol, 28, 552, 10.1038/modpathol.2014.153

Ok, 2015, Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases, Leuk Res, 39, 348, 10.1016/j.leukres.2014.12.006

Wong, 2015, Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia, Nature, 518, 552, 10.1038/nature13968

Kleiblova, 2013, Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint, J Cell Biol, 201, 511, 10.1083/jcb.201210031

Ruark, 2013, Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer, Nature, 493, 406, 10.1038/nature11725

Swisher, 2016, Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma, JAMA Oncol, 2, 370, 10.1001/jamaoncol.2015.6053

Zajkowicz, 2015, Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients, Br J Cancer, 112, 1114, 10.1038/bjc.2015.79

Pharoah, 2016, PPM1D mosaic truncating variants in ovarian cancer cases may be treatment-related somatic mutations, J Natl Cancer Inst, 108, djv347, 10.1093/jnci/djv347

Schulz, 2012, Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms, J Med Genet, 49, 422, 10.1136/jmedgenet-2011-100674

Churpek, 2016, Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia, Cancer, 122, 304, 10.1002/cncr.29615

Larson, 2012, Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms, J Clin Oncol, 30, 2300, 10.1200/JCO.2011.41.1215

Kröger, 2009, Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation, Haematologica, 94, 542, 10.3324/haematol.2008.000927

Kayser, 2011, The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML, Blood, 117, 2137, 10.1182/blood-2010-08-301713

Larson, 2011, Prognosis and therapy when acute promyelocytic leukemia and other “good risk” acute myeloid leukemias occur as a therapy-related myeloid neoplasm, Mediterr J Hematol Infect Dis, 3, e2011032, 10.4084/mjhid.2011.032

Fianchi, 2015, Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias, Am J Hematol, 90, E80, 10.1002/ajh.23966

Estey, 2015, Current challenges in clinical development of “targeted therapies”: the case of acute myeloid leukemia, Blood, 125, 2461, 10.1182/blood-2015-01-561373

Willyard, 2013, ‘Basket studies’ will hold intricate data for cancer drug approvals, Nat Med, 19, 655, 10.1038/nm0613-655

Boonstra, 2015, A statistical evaluation of dose expansion cohorts in phase I clinical trials, J Natl Cancer Inst, 107, dju429, 10.1093/jnci/dju429

Thall, 1999, A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials, Invest New Drugs, 17, 155, 10.1023/A:1006323317135

Walter, 2010, Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm, Blood, 116, 2420, 10.1182/blood-2010-05-285387

Estey, 2003, New designs for phase 2 clinical trials, Blood, 102, 442, 10.1182/blood-2002-09-2937

Hills, 2011, Applicability of a “Pick a Winner” trial design to acute myeloid leukemia, Blood, 118, 2389, 10.1182/blood-2011-02-337261

Korn, 2011, Outcome--adaptive randomization: is it useful?, J Clin Oncol, 29, 771, 10.1200/JCO.2010.31.1423

Iasonos, 2014, Adaptive dose-finding studies: a review of model-guided phase I clinical trials, J Clin Oncol, 32, 2505, 10.1200/JCO.2013.54.6051

Thall, 2008, Patient-specific dose finding based on bivariate outcomes and covariates, Biometrics, 64, 1126, 10.1111/j.1541-0420.2008.01009.x

Estey, 2016, New drug approvals in acute myeloid leukemia: what’s the best end point?, Leukemia, 30, 521, 10.1038/leu.2015.262

Luskin, 2014, Results of the ECOG E1900 trial in younger adults with AML using an event free survival endpoint are concordant with results based on overall survival: Potential for a surrogate endpoint to facilitate rapid approval of therapies in AML [abstract], Blood, 124, 10.1182/blood.V124.21.2599.2599

Othus, 2016, Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI, Haematologica, 101, e284, 10.3324/haematol.2015.138552

Schlenk, 2015, Event-free survival is a surrogate for overall survival in patients treated for acute myeloid leukemia [abstract], Blood, 126, 10.1182/blood.V126.23.3744.3744

Burnett, 2013, The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison, Leukemia, 27, 75, 10.1038/leu.2012.229

Burnett, 2013, Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival, Blood, 122, 1384, 10.1182/blood-2013-04-496596

Alibhai, 2009, Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia, Crit Rev Oncol Hematol, 69, 168, 10.1016/j.critrevonc.2008.07.015

Stein, 2016, Emerging therapeutic drugs for AML, Blood, 127, 71, 10.1182/blood-2015-07-604538

Grunwald, 2015, FLT3 tyrosine kinase inhibition as a paradigm for targeted drug development in acute myeloid leukemia, Semin Hematol, 52, 193, 10.1053/j.seminhematol.2015.03.004

Levis, 2011, Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse, Blood, 117, 3294, 10.1182/blood-2010-08-301796

Knapper

Serve, 2013, Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial, J Clin Oncol, 31, 3110, 10.1200/JCO.2012.46.4990

Röllig, 2015, Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial, Lancet Oncol, 16, 1691, 10.1016/S1470-2045(15)00362-9

Abdel-Wahab, 2013, Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia, Blood, 121, 3563, 10.1182/blood-2013-01-451781

Gallipoli, 2015, Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia, Ther Adv Hematol, 6, 103, 10.1177/2040620715577614

Issa, 2015, Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study, Lancet Oncol, 16, 1099, 10.1016/S1470-2045(15)00038-8

Wang, 2013, Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation, Science, 340, 622, 10.1126/science.1234769

Stein, 2015, Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: results of a phase 1/2 trial [abstract], Blood, 126, 10.1182/blood.V126.23.323.323

DiNardo, 2015, Molecular profiling and relationship with clinical response in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class potent inhibitor of mutant IDH1, in addition to data from the completed dose escalation portion of the phase 1 study [abstract], Blood, 126, 10.1182/blood.V126.23.1306.1306

Berthon, 2016, Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study, Lancet Haematol, 3, e186, 10.1016/S2352-3026(15)00247-1

Chen, 2015, Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond, Exp Hematol, 43, 673, 10.1016/j.exphem.2015.05.012

Placke, 2014, Requirement for CDK6 in MLL-rearranged acute myeloid leukemia, Blood, 124, 13, 10.1182/blood-2014-02-558114

Lichtenegger, 2015, Immunotherapy for acute myeloid leukemia, Semin Hematol, 52, 207, 10.1053/j.seminhematol.2015.03.006

Oberoi, 2014, Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis, Leuk Res, 38, 460, 10.1016/j.leukres.2014.01.004

Halpern, 2015, Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia, Blood, 126, 2790, 10.1182/blood-2015-07-627323

Wandt, 2012, Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study, Lancet, 380, 1309, 10.1016/S0140-6736(12)60689-8

Stanworth, 2013, A no-prophylaxis platelet-transfusion strategy for hematologic cancers, N Engl J Med, 368, 1771, 10.1056/NEJMoa1212772

Gröschel, 2015, Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways, Blood, 125, 133, 10.1182/blood-2014-07-591461